In Q4 2025, Cormorant Asset Management held 31 positions worth $1.8B. They initiated 1 new position and exited 67. Their largest holding was BBIO ($315.6M). Portfolio value grew +23.5% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q4 2025?
Cormorant Asset Management held 31 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include BBIO, PRAX, AAVXF, EYPT, RAPP. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q4 2025?
Cormorant Asset Management's tracked biotech portfolio was worth $1.8B across 31 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q4 2025?
Cormorant Asset Management initiated 1 new position in Q4 2025, including ASND. They also increased 5 existing positions.
What did Cormorant Asset Management sell in Q4 2025?
Cormorant Asset Management fully exited 67 positions in Q4 2025, including AUTL, IRON, KYTX, NKTX, RCKT and 62 more. They also trimmed 22 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Managementportfolio →